Summary
This 8-K filing from Regeneron Pharmaceuticals, Inc. (REGN) on December 23, 2005, details executive compensation decisions made by the Compensation Committee of the Board of Directors. The report outlines the approved 2006 annual salaries and year-end 2005 cash bonus awards for key named executive officers. These figures provide insight into the company's compensation strategy for its leadership team as it moves into the new fiscal year. For investors, this filing offers transparency into how the company is rewarding its top executives, reflecting potential confidence in their continued leadership and performance. The disclosed salary increases, while modest, and the bonus amounts can be interpreted as indicators of the company's financial health and its commitment to retaining its key talent. Investors may use this information to gauge executive incentives and align their expectations with the company's operational and strategic direction.
Key Highlights
- 1The Compensation Committee approved 2006 annual salaries and 2005 year-end cash bonuses for named executive officers.
- 2CEO Leonard S. Schleifer, M.D., Ph.D. will receive a 2006 salary of $685,000 with a 2.9% increase from 2005, and a cash bonus of $340,000.
- 3Chief Scientific Officer George D. Yancopoulos, M.D., Ph.D. will receive a 2006 salary of $544,300 with a 4.5% increase, and a cash bonus of $280,000.
- 4CFO Murray A. Goldberg will receive a 2006 salary of $374,300 with a 5.0% increase, and a cash bonus of $179,700.
- 5Other key executives, including Senior Vice Presidents Neil Stahl, Ph.D., and Randall G. Rupp, Ph.D., also received salary increases and cash bonuses.
- 6The report demonstrates the company's formal process for setting executive compensation.
- 7Bonuses were paid in January 2006, reflecting performance from the 2005 fiscal year.